[HTML][HTML] Monkeypox virus infection in humans across 16 countries—April–June 2022
…, JI Lezama, C Mussini, AM Cattelan… - … England Journal of …, 2022 - Mass Medical Soc
Background Before April 2022, monkeypox virus infection in humans was seldom reported
outside African regions where it is endemic. Currently, cases are occurring worldwide. …
outside African regions where it is endemic. Currently, cases are occurring worldwide. …
Abnormal liver function tests predict transfer to intensive care unit and death in COVID‐19
…, A Martini, MM Luchetti, R Serra, A Cattelan… - Liver …, 2020 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has emerged as a
relevant threat for humans worldwide. Abnormality in liver function tests (LFTs) has been …
relevant threat for humans worldwide. Abnormality in liver function tests (LFTs) has been …
[HTML][HTML] Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients
…, D Marturano, A Zaramella, S Realdon, A Cattelan… - Cell death & …, 2020 - nature.com
A global effort is currently undertaken to restrain the COVID-19 pandemic. Host immunity
has come out as a determinant for COVID-19 clinical outcomes, and several studies …
has come out as a determinant for COVID-19 clinical outcomes, and several studies …
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
M Bassetti, N Castaldo, A Cattelan, C Mussini… - International journal of …, 2019 - Elsevier
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for
different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 …
different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 …
Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
Background Vaccine-induced population immunity is a key global strategy to control coronavirus
disease 2019 (COVID-19). The rapid implementation and availability of several COVID-…
disease 2019 (COVID-19). The rapid implementation and availability of several COVID-…
[HTML][HTML] Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial
…, RL Gottlieb, GJ Criner, JRA López, AM Cattelan… - Jama, 2020 - jamanetwork.com
Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …
Mpox in people with advanced HIV infection: a global case series
…, C Hoffmann, K Protopapas, S Nozza, AM Cattelan… - The Lancet, 2023 - thelancet.com
Background People living with HIV have accounted for 38–50% of those affected in the 2022
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and …
…, E Barchi, P Caramello, F Castelli, AM Cattelan… - The Lancet, 2019 - thelancet.com
Background Effective two-drug regimens could decrease long-term drug exposure and toxicity
with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and …
with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and …
Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration
…, F Ghirardini, S Tresso, AM Cattelan… - Diabetes research and …, 2020 - Elsevier
Aims We investigated whether pre-existing diabetes, newly-diagnosed diabetes, and admission
hyperglycemia were associated with COVID-19 severity independently from confounders…
hyperglycemia were associated with COVID-19 severity independently from confounders…
COVID‐19 and venous thromboembolism in intensive care or medical ward
…, M Cola, P Navalesi, A Cattelan… - Clinical and …, 2020 - Wiley Online Library
Despite thromboprophylaxis, patients with coronavirus disease 2019 (COVID‐19) exhibit
hypercoagulability and higher venous thromboembolic risk, although its real incidence is still …
hypercoagulability and higher venous thromboembolic risk, although its real incidence is still …
